Payment overview · 2025
General Payments
$282.98
11 reported records · 5 companies
Healthcare provider profile · identity verified
Jon Mark Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STILLWATER, OK · NPI 1598765497
Verified facts
What the public records show
CMS Open Payments records show Jon Mark Johnson, M.D. received $282.98 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 57.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $163.11 | 57.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.31 | 21.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.31 | 7.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.03 | 7.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.22 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $282.98 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $163.11 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $11.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 94 |
| Losartan Potassium | Losartan Potassium | 349 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 92 |
| Lisinopril | Lisinopril | 274 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 67 |
| Metformin Hcl Er | Metformin Hcl | 202 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 46 |
| Gabapentin | Gabapentin | 166 | 42 |
| Metformin Hcl | Metformin Hcl | 166 | 43 |
| Simvastatin | Simvastatin | 164 | 38 |
| Omeprazole | Omeprazole | 131 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 30 |
| Trazodone Hcl | Trazodone Hcl | 108 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 26 |
| Jardiance | Empagliflozin | 103 | 17 |
| Alendronate Sodium | Alendronate Sodium | 100 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 23 |
| Montelukast Sodium | Montelukast Sodium | 95 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 22 |
| Allopurinol | Allopurinol | 82 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 19 |
| Potassium Chloride | Potassium Chloride | 74 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 19 |
| Sertraline Hcl | Sertraline Hcl | 70 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 24 |
| Meloxicam | Meloxicam | 61 | 17 |
| Carvedilol | Carvedilol | 60 | 16 |
| Glimepiride | Glimepiride | 59 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Donepezil Hcl | Donepezil Hcl | 58 | 12 |
| Celecoxib | Celecoxib | 57 | 28 |
| Tramadol Hcl | Tramadol Hcl | 54 | 12 |
| Baclofen | Baclofen | 48 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Ozempic | Semaglutide | 47 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Furosemide | Furosemide | 43 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 32 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Prednisone | Prednisone | 33 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Estradiol | Estradiol | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 21 |
| Nystatin | Nystatin | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $282.98 · 11 records | Amgen Inc. | EVENITY, FREESTYLE LIBRE 3, INTELLIS ADAPTIVESTIM, JARDIANCE, MOUNJARO, PROLIA, YUPELRI, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error